Orlistat mouth rinse: Using the tongue to deliver antiobesity medication in a double-blind randomized crossover pilot trial

Diabetes Obes Metab. 2023 Aug;25(8):2236-2242. doi: 10.1111/dom.15101. Epub 2023 May 3.

Abstract

Aim: To investigate the effects of an orlistat mouth rinse on the intake of a high-fat meal.

Methods: A double-blind, balanced order, crossover study was conducted in participants (n = 10, body mass index 25-30 kg/m2 ) assigned to receive placebo or orlistat (24 mg/mL) prior to a high-fat meal. Participants were divided into low- or high-fat consumers based on calories consumed from fat following placebo administration.

Results: The orlistat mouth rinse decreased total and fat calories consumed during the high-fat meal in high-fat consumers, and did not alter calories consumed in low-fat consumers (P < 0.05).

Conclusions: Orlistat decreases long-chain fatty acid (LCFA) absorption by inhibiting lipases that breakdown triglycerides. Orlistat mouth rinse decreased fat intake in high-fat consumers, suggesting that orlistat inhibited the detection of LCFAs from the high-fat test meal. Lingual delivery of orlistat is predicted to eliminate the risk of oil incontinence and promote weight loss in individuals who prefer fat.

Keywords: fat sensing; obesity; orlistat; tongue.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Anti-Obesity Agents* / adverse effects
  • Cross-Over Studies
  • Double-Blind Method
  • Humans
  • Lactones / adverse effects
  • Mouthwashes* / therapeutic use
  • Obesity / complications
  • Obesity / drug therapy
  • Orlistat / therapeutic use
  • Pilot Projects

Substances

  • Orlistat
  • Mouthwashes
  • Lactones
  • Anti-Obesity Agents